[논문]IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism

Vigo, Tiziana; La Rocca, Claudia; Faicchia, Deriggio; Procaccini, Claudio; Ruggieri, Maddalena; Salvetti, Marco; Centonze, Diego; Matarese, Giuseppe; Uccelli, Antonio

doi:10.1038/s41419-019-1336-4

IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism 원문보기

Cell death & disease, v.10 no.2, 2019년, pp.85 -

Vigo, Tiziana (IRCCS Ospedale Policlinico San Martino, Genoa, Italy) , La Rocca, Claudia (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Faicchia, Deriggio (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Procaccini, Claudio (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Ruggieri, Maddalena (Department of Basic Medical Science, Neuroscience and Sense Organs, University of Bari, Bari, Italy) , Salvetti, Marco (Centre for Experimental Neurological Therapies (CENTERS), Sapienza University, Rome, Italy) , Centonze, Diego (IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed, Pozzilli, Italy) , Matarese, Giuseppe (Laboratorio di Immunologia, Istituto di Endocrinologia e Oncologia Sperimentale, Consiglio Nazionale delle Ricerche (IEOS-CNR), Naples, Italy) , Uccelli, Antonio (IRCCS Ospedale Policlinico San Martino, Genoa, Italy)

Abstract ▼ AI-Helper

Administration of mesenchymal stem cells (MSC) ameliorate experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS), at both clinical and neuropathological levels. The therapeutic properties of MSC in EAE are mainly mediated by the modulation of pathogenic immune response, but other neurotropic effects, including decreased demyelination and axonal loss as well as promotion of tissue repair, play also a role. Properly controlled phase II clinical trials to explore the potential of MSC transplantation as a treatment for MS are underway. Interferon beta (IFNβ) is an approved treatment for relapsing-remitting and secondary progressive MS. Here, we explored the possibility that IFNβ might influence the therapeutic potential of MSC, in view of possible synergistic effects as add-on therapy. IFNβ enhanced the immunomodulatory functions of MSC and induced the expression of secretory leukocyte protease inhibitor (Slpi) and hepatocyte growth factor (Hgf), two soluble mediators involved in immune and regenerative functions of MSC. At molecular level, IFNβ induced a rapid and transient phosphorylation of STAT1 and STAT3, the transcription factors responsible for Slpi and Hgf induction. Concomitantly, IFNβ dynamically affected the activity of mTOR, a key checkpoint in the control of metabolic pathways. Indeed, the impairment of mTOR activity observed early upon exposure to IFNβ, was followed by a long-lasting induction of mTOR signaling, that was associated with an increased glycolytic capacity in MSC. When induced to switch their energetic metabolism towards glycolysis, MSC showed an improved ability to control T-cell proliferation. These results suggest that modifications of MSC energetic metabolism induced by IFNβ may contribute to promote MSC immunomodulatory function and support a role for metabolic pathways in the therapeutic function of MSC. Altogether, these findings support the idea of a combined treatment for MS, in which the immunomodulatory and possibly regenerative activity of MSC could be enhanced by the administration of IFNβ.

참고문헌 (32)

1. Horwitz EM Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement Cytotherapy 2005 7 393 395 10.1080/14653240500319234 16236628

상세보기
2. Uccelli A Moretta L Pistoia V Mesenchymal stem cells in health and disease Nat. Rev. Immunol. 2008 8 726 736 10.1038/nri2395 19172693

상세보기
3. Uccelli A Laroni A Freedman MS Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases Lancet Neurol. 2011 10 649 656 10.1016/S1474-4422(11)70121-1 21683930

상세보기
4. Bai L Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis Glia 2009 57 1192 1203 10.1002/glia.20841 19191336

상세보기
5. Gerdoni E Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis Ann. Neurol. 2007 61 219 227 10.1002/ana.21076 17387730

상세보기
6. Gordon D Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration Neurosci. Lett. 2008 448 71 73 10.1016/j.neulet.2008.10.040 18950680

상세보기
7. Rafei, M. et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182 , 5994？6002 (2009).
8. Zappia E Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy Blood 2005 106 1755 1761 10.1182/blood-2005-04-1496 15905186

상세보기
9. Zhang J Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice Exp. Neurol. 2005 195 16 26 10.1016/j.expneurol.2005.03.018 15904921

상세보기
10. Ren G Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide Cell Stem Cell 2008 2 141 150 10.1016/j.stem.2007.11.014 18371435

상세보기
11. Vigo T IFN-gamma orchestrates mesenchymal stem cell plasticity through the signal transducer and activator of transcription 1 and 3 and mammalian target of rapamycin pathways J. Allergy Clin. Immunol. 2017 139 1667 1676 10.1016/j.jaci.2016.09.004 27670240

상세보기
12. Bai L Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models Nat. Neurosci. 2012 15 862 870 10.1038/nn.3109 22610068

상세보기
13. Connick P Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study Lancet Neurol. 2012 11 150 156 10.1016/S1474-4422(11)70305-2 22236384

상세보기
14. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352 , 1498？1504 (1998)..
15. Platanias LC Fish EN Signaling pathways activated by interferons Exp. Hematol. 1999 27 1583 1592 10.1016/S0301-472X(99)00109-5 10560905

상세보기
16. Severa M Rizzo F Giacomini E Salvetti M Coccia EM IFN-beta and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks Cytokine Growth Factor Rev. 2015 26 229 239 10.1016/j.cytogfr.2014.11.005 25498525

상세보기
17. Severa M IFN-beta therapy regulates TLR7-mediated response in plasmacytoid dendritic cells of multiple sclerosis patients influencing an anti-inflammatory status J. Interferon Cytokine Res. 2015 35 668 681 10.1089/jir.2014.0207 25923141

상세보기
18. Alenda R Blood lymphocyte subsets identify optimal responders to IFN-beta in MS 2018 265 24 31
19. Vandenbark AA Interferon-beta-1a treatment increases CD56 bright natural killer cells and CD4+CD25+Foxp3 expression in subjects with multiple sclerosis J. Neuroimmunol. 2009 215 125 128 10.1016/j.jneuroim.2009.08.007 19758707

상세보기
20. Majchrzak-Gorecka, M., Majewski, P., Grygier, B., Murzyn, K. & Cichy, J. Secretory leukocyte protease inhibitor (SLPI), a multifunctional protein in the host defense response. Cytokine Growth Factor Rev . 10.1016/j.cytogfr.2015.12.001 (2015).
21. De Rosa V A key role of leptin in the control of regulatory T cell proliferation Immunity 2007 26 241 255 10.1016/j.immuni.2007.01.011 17307705

상세보기
22. Kasper LH Reder AT Immunomodulatory activity of interferon-beta Ann. Clin. Transl. Neurol. 2014 1 622 631 10.1002/acn3.84 25356432

상세보기
23. Croitoru-Lamoury J Lamoury FM Zaunders JJ Veas LA Brew BJ Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone J. Interferon Cytokine Res. 2007 27 53 64 10.1089/jir.2006.0037 17266444

상세보기
24. Taggart CC Secretory leucoprotease inhibitor binds to NF-kappaB binding sites in monocytes and inhibits p65 binding J. Exp. Med. 2005 202 1659 1668 10.1084/jem.20050768 16352738

상세보기
25. Guerrieri D Serine leucocyte proteinase inhibitor-treated monocyte inhibits human CD4(+) lymphocyte proliferation Immunology 2011 133 434 441 10.1111/j.1365-2567.2011.03451.x 21574992

상세보기
26. Tateosian NL Neutrophil elastase treated dendritic cells promote the generation of CD4(+)FOXP3(+) regulatory T cells in vitro Cell Immunol. 2011 269 128 134 10.1016/j.cellimm.2011.03.013 21477798

상세보기
27. Mueller AM Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis J. Neuroinflamm. 2008 5 20 10.1186/1742-2094-5-20

상세보기
28. Norata GD The cellular and molecular basis of translational immunometabolism Immunity 2015 43 421 434 10.1016/j.immuni.2015.08.023 26377896

상세보기
29. Fischer K Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 2007 109 3812 3819 10.1182/blood-2006-07-035972 17255361

상세보기
30. Dietl K Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes J. Immunol. 2010 184 1200 1209 10.4049/jimmunol.0902584 20026743

상세보기
31. Marin-Banasco C Gene therapy with mesenchymal stem cells expressing IFN-ss ameliorates neuroinflammation in experimental models of multiple sclerosis Br. J. Pharmacol. 2017 174 238 253 10.1111/bph.13674 27882538

상세보기
32. Kim MJ Effective combination of methylprednisolone and interferon beta-secreting mesenchymal stem cells in a model of multiple sclerosis J. Neuroimmunol. 2018 314 81 88 10.1016/j.jneuroim.2017.11.010 29224961

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

IFNβ enhances mesenchymal stromal (Stem) cells immunomodulatory function through STAT1-3 activation and mTOR-associated promotion of glucose metabolism 원문보기

Abstract ▼ AI-Helper

참고문헌 (32)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트